Filtered By:
Specialty: Endocrinology
Condition: Congestive Heart Failure

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 48 results found since Jan 2013.

Risk of ischemic stroke after third, fourth, and sixth cranial nerve palsies in type 2 diabetes
ConclusionsPhysicians should pay more attention to manageable risk factors of ischemic stroke when diabetic patients suffer from ocular motor CN palsies.
Source: Journal of Diabetes - November 15, 2018 Category: Endocrinology Authors: Sang Jun Park, Hee Kyung Yang, Seong Jun Byun, Kyu Hyung Park, Jeong ‐Min Hwang Tags: ORIGINAL ARTICLE Source Type: research

Testosterone replacement therapy in relation with cardiovascular disease in cisgender women and transgender people
CONCLUSION: Use of TTh increased the risk of CVD, CAD and stroke among is cisgender women, but not among transgender people. TTh is becoming more widely accepted in women, and it is the main medical treatment for transgender males. Therefore, use of TTh should be further investigated for the prevention of CVD.PMID:37392459 | DOI:10.1210/clinem/dgad388
Source: The Journal of Clinical Endocrinology and Metabolism - July 1, 2023 Category: Endocrinology Authors: David S Lopez Juwairia S Mulla Danielle El Haddad Md Ibrahim Tahashilder Efstathia Polychronopolou Jacques Baillargeon Yong-Fang Kuo Syed Gilani Wissam I Khalife Source Type: research

Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: A nation-wide follow-up study during 1998-2009.
ConclusionsDiabetes and ESRD synergistically increase risks of CV events. Proactive screening and control for diabetes in patients with ESRD should be built into our daily practice. PMID: 23920086 [PubMed - as supplied by publisher]
Source: Diabetes Care - August 6, 2013 Category: Endocrinology Authors: Chang YT, Wu JL, Hsu CC, Wang JD, Sung JM Tags: Diabetes Care Source Type: research

Annual direct medical costs associated with diabetes ‐related complications in the event year and in subsequent years in Hong Kong
ConclusionsWide variations in direct medical cost in event year and subsequent years across different major complications were observed. Input of these data would be essential for economic evaluations of diabetes management programmes.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - June 21, 2017 Category: Endocrinology Authors: F. Jiao, C. K. H. Wong, S. C. W. Tang, C. S. C. Fung, K. C. B. Tan, S. McGhee, R. Gangwani, C. L. K. Lam Tags: Research Article Source Type: research

The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
Conclusions/interpretationSGLT2i and GLP-1RA are superior to DPP-4i in terms of CV and renal outcomes. GLP-1RA is the only drug class that reduces the risk of stroke. SGLT2i is superior in reducing HHF and renal outcomes. Therefore, the choice between SGLT2i and GLP-1RA should be individualised according to patient profiles.PROSPERO registration number: CRD42020206600.Graphical abstract
Source: Diabetologia - November 2, 2021 Category: Endocrinology Source Type: research

Cardiovascular Risk Associated with Acarbose versus Metformin as the First-line Treatment in Patients with Type 2 Diabetes: a Nationwide Cohort Study.
Conclusion: Our data do not support that acarbose has a cardio-protective effect similar to metformin as a first-line anti-diabetic agent. PMID: 25555040 [PubMed - as supplied by publisher]
Source: Diabetes Metab - January 2, 2015 Category: Endocrinology Authors: Chang C, Chang Y, Lin J, Chen S, Chuang L, Lai M Tags: J Clin Endocrinol Metab Source Type: research

Cardiovascular risks associated with second‐line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study
ConclusionThere were no differences in overall cardiovascular risks among several add‐on second‐line oral antidiabetic agents; however, glinide plus metformin and α‐glucosidase inhibitors plus metformin combination therapies might be associated with lower risks of acute myocardial infarction.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - May 1, 2015 Category: Endocrinology Authors: Y.‐C. Chang, L.‐M. Chuang, J.‐W. Lin, S.‐T. Chen, M.‐S. Lai, C.‐H. Chang Tags: Research Article Source Type: research

Acute Kidney Injury Predicts Major Adverse Outcomes in Diabetes: Synergic Impact With Low Glomerular Filtration Rate and Albuminuria
CONCLUSIONS AKI, low eGFR, and elevated albuminuria, separately or together, are compelling biomarkers of major adverse outcomes and death in diabetes.
Source: Diabetes Care - November 24, 2015 Category: Endocrinology Authors: Monseu, M.; Gand, E.; Saulnier, P.-J.; Ragot, S.; Piguel, X.; Zaoui, P.; Rigalleau, V.; Marechaud, R.; Roussel, R.; Hadjadj, S.; Halimi, J.-M.; for the SURDIAGENE Study Group Tags: Pathophysiology/Complications Source Type: research

Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
CONCLUSIONS Intensive diabetes therapy during the DCCT (6.5 years) has long-term beneficial effects on the incidence of cardiovascular disease in type 1 diabetes that persist for up to 30 years.
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group Tags: Cardiovascular Disease and Diabetes Source Type: research

Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi ‐database, non‐interventional post‐authorization safety study
Abstract This non‐interventional, multi‐database, analytical cohort study assessed the cardiovascular (CV) safety of vildagliptin vs. other non‐insulin antidiabetic drugs (NIADs) using real‐world data from five European electronic healthcare databases. Patients with type 2 diabetes aged ≥18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regressio...
Source: Diabetes, Obesity and Metabolism - March 24, 2017 Category: Endocrinology Authors: R. Williams, F. de Vries, W. Kothny, C. Serban, S. Lopez ‐Leon, C. Chu, R. Schlienger Tags: BRIEF REPORT Source Type: research

Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users
ConclusionsThis study provides evidence of increased CVD risk associated with hypoglycaemia, especially serious hypoglycaemia events. While associations were attenuated with non‐serious hypoglycaemia, the results were suggestive of a potential increased risk.
Source: Diabetes, Obesity and Metabolism - May 1, 2017 Category: Endocrinology Authors: Anthony P. Nunes, Kristy Iglay, Larry Radican, Samuel S. Engel, Jing Yang, Michael C. Doherty, David D. Dore Tags: ORIGINAL ARTICLE Source Type: research

Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials
Publication date: Available online 10 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Sanjay Basu, Jeremy B Sussman, Seth A Berkowitz, Rodney A Hayward, John S Yudkin Background In view of substantial mis-estimation of risks of diabetes complications using existing equations, we sought to develop updated Risk Equations for Complications Of type 2 Diabetes (RECODe). Methods To develop and validate these risk equations, we used data from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD, n=9635; 2001–09) and validated the equations for microvascular events using data from the Di...
Source: The Lancet Diabetes and Endocrinology - August 11, 2017 Category: Endocrinology Source Type: research